HIV/AIDS deaths in the U.S. have dropped significantly in recent years. In 1995, the death rate from HIV per 100,000 people was ****. That number has since decreased to *** per 100,000 as of 2023. The reduction in the HIV death rate in the U.S. can be attributed to an increase in access to HIV medications. HIV/AIDS in the U.S. Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) cause a systemic viral infection that damages the immune system. AIDS is a syndrome that is caused by HIV. AIDS is when the immune system is severely weakened by HIV and the body can no longer fight off infections. Among all U.S. states, Georgia, followed by Florida and Louisiana, had the highest rates of new HIV diagnoses in 2022. HIV/AIDS treatments in the U.S. HIV/AIDS treatments include antiretroviral medications to reduce the levels of HIV within the body. The largest funders for HIV/AIDS medications and research are the National Institutes of Health (NIH) and the Ryan White Program. The top HIV drug worldwide, based on revenue generated in 2023 was Biktarvy. Around the world, access to antiretroviral treatment has increased dramatically in recent years, a huge step in reducing the number of HIV-related deaths. There is currently no cure for HIV.

UNAIDS estimated that there were some ******* people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2024. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2024. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2024, the highest number of AIDS-related deaths occurred in South Africa and Mozambique and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost ** million in 2024. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.

IntroductionMozambique continues to face a severe HIV epidemic and high cost for its control, largely born by international donors. We assessed feasible targets, likely impact and costs for the 2015–2019 national strategic HIV/AIDS plan (NSP).MethodsThe HIV epidemic and response was modelled in the Spectrum/Goals/Resource Needs dynamical simulation model, separately for North/Center/South regions, fitted to antenatal clinic surveillance data, household and key risk group surveys, program statistics, and financial records. Intervention targets were defined in collaboration with the National AIDS Council, Ministry of Health, technical partners and implementing NGOs, considering existing commitments.ResultsImplementing the NSP to meet existing coverage targets would reduce annual new infections among all ages from 105,000 in 2014 to 78,000 in 2019, and reduce annual HIV/AIDS-related deaths from 80,000 to 56,000. Additional scale-up of prevention interventions targeting high-risk groups, with improved patient retention on ART, could further reduce burden to 65,000 new infections and 51,000 HIV-related deaths in 2019. Program cost would increase from US$ 273 million in 2014, to US$ 433 million in 2019 for ‘Current targets’, or US$ 495 million in 2019 for ‘Accelerated scale-up’. The ‘Accelerated scale-up’ would lower cost per infection averted, due to an enhanced focus on behavioural prevention for high-risk groups. Cost and mortality impact are driven by ART, which accounts for 53% of resource needs in 2019. Infections averted are driven by scale-up of interventions targeting sex work (North, rising epidemic) and voluntary male circumcision (Center & South, generalized epidemics).ConclusionThe NSP could aim to reduce annual new HIV infections and deaths by 2019 by 30% and 40%, respectively, from 2014 levels. Achieving incidence and mortality reductions corresponding to UNAIDS’ ‘Fast track’ targets will require increased ART coverage and additional behavioural prevention targeting key risk groups.

The states with the highest rates of HIV diagnoses in 2022 included Georgia, Louisiana, and Florida. However, the states with the highest number of people with HIV were Texas, California, and Florida. In Texas, there were around 4,896 people diagnosed with HIV. HIV/AIDS diagnoses In 2022, there were an estimated 38,043 new HIV diagnoses in the United States, a slight increase compared to the year before. Men account for the majority of these new diagnoses. There are currently around 1.2 million people living with HIV in the United States. Deaths from HIV The death rate from HIV has decreased significantly over the past few decades. In 2023, there were only 1.3 deaths from HIV per 100,000 population, the lowest rate since the epidemic began. However, the death rate varies greatly depending on race or ethnicity, with the death rate from HIV for African Americans reaching 19.2 per 100,000 population in 2022, compared to just three deaths per 100,000 among the white population.

This scatter chart displays death rate (per 1,000 people) against incidence of HIV (per 1,000 uninfected population) in Central America. The data is about countries per year.

United States US: Maternal Mortality Ratio: Modeled Estimate: per 100,000 Live Births data was reported at 14.000 Ratio in 2015. This stayed constant from the previous number of 14.000 Ratio for 2014. United States US: Maternal Mortality Ratio: Modeled Estimate: per 100,000 Live Births data is updated yearly, averaging 13.000 Ratio from Dec 1990 (Median) to 2015, with 26 observations. The data reached an all-time high of 15.000 Ratio in 2009 and a record low of 11.000 Ratio in 1998. United States US: Maternal Mortality Ratio: Modeled Estimate: per 100,000 Live Births data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Maternal mortality ratio is the number of women who die from pregnancy-related causes while pregnant or within 42 days of pregnancy termination per 100,000 live births. The data are estimated with a regression model using information on the proportion of maternal deaths among non-AIDS deaths in women ages 15-49, fertility, birth attendants, and GDP.; ; WHO, UNICEF, UNFPA, World Bank Group, and the United Nations Population Division. Trends in Maternal Mortality: 1990 to 2015. Geneva, World Health Organization, 2015; Weighted average; This indicator represents the risk associated with each pregnancy and is also a Sustainable Development Goal Indicator for monitoring maternal health.

United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 14.600 % in 2016. This records an increase from the previous number of 14.300 % for 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 14.600 % from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 18.000 % in 2000 and a record low of 14.300 % in 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted Average;

United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 11.800 NA in 2016. This records an increase from the previous number of 11.600 NA for 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 11.800 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 14.600 NA in 2000 and a record low of 11.600 NA in 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

Tuberculosis is one of the deadliest communicable diseases worldwide, causing around *** million deaths per year. Communicable diseases, also known as infectious diseases, are spread from person to person either directly or indirectly, such as through an insect bite or ingesting contaminated food or water. Some of the deadliest communicable diseases include HIV/AIDS, malaria, hepatitis C, cholera, and measles. Tuberculosis Tuberculosis is an infectious disease that affects the lungs. Tuberculosis disproportionately impacts the poorer, less developed countries of the world, such as in Africa and Southeast Asia. India reports the highest number of deaths from tuberculosis worldwide. HIV/AIDS Although deaths from HIV/AIDS have decreased over the last few decades, there were still around ******* AIDS-related deaths in 2023. Like many other communicable diseases, HIV/AIDS impacts developing regions more than the developed world. By far, the highest number of AIDS deaths come from Africa and Asia Pacific. Advancements in HIV treatment now allow those infected to live long and relatively normal lives, but access to treatment varies greatly.

Globally, over many years, one of the top drugs for the treatment of HIV/AIDS is Genvoya, marketed by Gilead. In 2024, Genvoya still generated around *** billion U.S. dollars in revenue. Biktarvy, also marketed by Gilead, was the best-selling HIV/AIDS treatment and generated around **** billion U.S. dollars in revenue. Gilead is the drug manufacturer most specialized in developing drugs for the treatment of HIV/AIDS. HIV/AIDS cases worldwide HIV is a virus that attacks the immune system, leading to an increased risk of infections and can lead to death. HIV/AIDS first appeared in global populations in the 1980s. According to current estimates, the prevalence of HIV is highest in low and middle income countries. Eswatini, followed by Lesotho, had the highest rates of HIV infections in 2023. The number of new HIV infections by world region is highest among residents of Eastern and Southern Africa. Access to HIV/AIDS treatment Effective treatment for HIV was not available until the early 1990s. Access to therapy has increased since the early 2000s, and as of 2022 there were approximately ** million people that had access to antiretroviral therapy. Among countries around the world, Uganda, India and Kenya, to name a few, have the lowest rates of access to antiretroviral medications for the treatment of HIV/AIDS.